In the phase 3 OptiTROP-Lung06 study, which was run by Kelun in 455 Chinese patients, sac-TMT reduced the risk of disease ...

Nubeqa is a key growth product for Bayer, with sales up around 60% to €1.63 billion in the first half of this year from its ...

The full look at the results of the DeLLphi-305 study of Imdelltra (tarlatamab) and Imfinzi (durvalumab) as first-line maintenance therapy for extensive-stage SCLC (ES-SCLC) whose disease had not ...

VOLGA was conducted in patients with MIBC ineligible or unwilling to take platinum-based chemotherapy, who received PD-L1 inhibitor Imfinzi (durvalumab) before and after surgery to remove the tumour, ...

Sofe-m was acquired by Lilly as part of its 2023 takeover of French biotech Mablink Bioscience and its PSARLink ADC ...

A drug at the heart of Johnson & Johnson's $3 billion takeover of Halda last year, JNJ-6143, has shown promise in an ...

Two drugs hoping to muscle in Amgen's first-to-market DLL3-targeting drug Imdelltra – from Zai Lab and Ideaya – have new ...

Autolus' CAR-T cell therapy for a rare and aggressive form of acute lymphoblastic leukaemia (ALL), Aucatzyl, has been recommended for conditional approval in the EU. The EMA's human medicines ...

As the European Society for Medical Oncology 2026 Congress commences in Madrid, pharmaphorum invited Syncromune Executive ...

The most consequential changes in cancer biology can often occur before they become visible on a scan. Yet, modern cancer ...

An overview of the NHS’s AI-Assisted Discharge Summarisation (AADS) project and what it takes to move AI beyond the pilot ...